Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.48 |
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | ACACB | O00763 | 4/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18164352 | 0.89 | GRM2 (0.39) | GRM2CNR2ACACBPTGER4GRIN1 | |
| SCHEMBL18164351 | 0.86 | GRM2 (0.37) | GRM2CNR2ACACBPTGER4GRIN1 | |
| SCHEMBL23073274 | 0.83 | GRM2 (0.35) | GRM2CNR2ACACB | |
| SCHEMBL18152777 | 0.82 | GRM2 (0.34) | GRM2CNR2ACACBKCNH2 | |
| SCHEMBL23473109 | 0.81 | CNR2 (0.33) | GRM2CNR2ACACBGRIN1GRIN2B | |
| SCHEMBL18164550 | 0.81 | CNR2 (0.36) | GRM2CNR2ACACBGRIN1GRIN2B | |
| SCHEMBL8010918 | 0.76 | EGFR (0.41) | GRM2 | |
| SCHEMBL18164393 | 0.71 | GRM2 (0.37) | GRM2CNR2 | |
| SCHEMBL18164379 | 0.69 | GRM2 (0.36) | GRM2CNR2GRIN1GRIN2BKCNH2 | |
| SCHEMBL18152808 | 0.69 | CNR2 (0.37) | GRM2CNR2ACACBGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | GRM2 2764/4885CNR2 3909/4885ACACB 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.